跳到正文
原文
Endpoints News 生物医药· Max Bayer·· 17 天前AI 评分35

Pfizer 调高 2026 年度指引,肿瘤与偏头痛业务增长抵消新冠产品下滑

Pfizer lifts 2026 guidance as cancer, migraine sales offset Covid slide

AI 导读

Pfizer 调高 2026 年度财务指引,得益于肿瘤和偏头痛业务的强劲增长,抵消了新冠产品销售的显著下滑。

正文

Pfiz­er raised its 2026 fi­nan­cial guid­ance as strong growth in its on­col­o­gy and mi­graine busi­ness­es helped it weath­er sharp sales drops in its Covid prod­ucts.

…

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news